We are delighted to announce that Professor James Chalmers, MBChB, PhD, FRCPE, FERS, Rhodes Professor of Experimental Therapeutics and Clinical Pharmacology at the University of Oxford, is joining the scientific advisory board of MCC Therapeutics, Inc. Previously, Professor Chalmers was GSK/Asthma and Lung UK Professor of Respiratory Medicine at the University of Dundee.

Professor Chalmers is an active clinician running a specialist clinic for patients with difficult respiratory infections, particularly bronchiectasis.

He has published more than 550 peer reviewed manuscripts and chaired several international guideline panels including the 2017 European Bronchiectasis Guidelines, the 2020 European Guidelines for ICS use in COPD, the European Respiratory Society Living Guideline for Management of Hospitalized Patients with COVID-19 and the upcoming European Respiratory Society Guidelines for the Management of Bronchiectasis in Adults. He was appointed as Deputy Chief Editor of the European Respiratory Journal and was appointed Chief Editor in 2018. He is current Chair of the Science and Research Committee of the British Thoracic Society and co-Chairs the Scottish Government Chief Scientist Office Translational Clinical Studies Committee.

Dr. Chalmers is leading the world’s premier research center for the study of bronchiectasis, a chronic respiratory disease affecting more than 1,000,000 people worldwide. His group at the University of Oxford hosts the EMBARC European Bronchiectasis Network and leads multiple international studies including a number of randomized clinical trials of novel therapies with academic partners and international pharmaceutical companies.

Dr. Chalmers’ research was instrumental to the development of several therapies for the treatment of chronic inflammatory lung diseases and he was the principal investigator on the trials leading to the approval of Insmed’s Bersocatib (Brinsupri), the only drug approvedfor the treatment of bronchiectasis.

“Mucus obstruction is one of the central pillars in the vicious vortex resulting in the development and progression of bronchiectasis”, said Dr. Chalmers, “moving obstructed mucus and potentially relieving mucus plugging in patients with bronchiectasis, cystic fibrosis and other lung diseases, is critical to managing progressing symptoms with significant effects on our patient’s quality of life and mortality. Looking at the promising safety and clinical signal observed in the early trial of MCCSA2 in healthy volunteers and patients with cystic fibrosis, I’m excited to join MCC Therapeutics’ team and help in the design and development of their drug, MCCSA2, for the treatment of mucus obstruction”.

Mucociliary clearance (MCC), mediated by the actions of diverse conducting airway and submucosal gland epithelial cells, plays a critical role in a multilayered defense system by secreting fluids, electrolytes, antimicrobial and anti-inflammatory proteins, and mucus onto airway surfaces. Although mucus and other airway epithelial secretions play a critical role in protecting the lung during acute injury, impaired mucus clearance after chronic mucus hyperproduction causes airway obstruction and infection, which contributes to morbidity in common pulmonary disorders, including bronchiectasis, COPD, asthma, cystic fibrosis, and primary ciliary dyskinesia.

“MCC Therapeutics, Inc. welcomes Dr. Chalmers to MCCs scientific advisory board”, said Dr. Isaac Cohen, MCC Theraputics’ CEO. “Dr. Chalmers brings significant additional expertise to our company. His role will be central to the design and development of MCCSA2 in the treatment of mucociliary clearance in bronchiectasis”.

MCC Therapeutics is planning to launch a Phase 1 single ascending dose, followed by a multiple ascending dose clinical trial in bronchiectasis (NCFB) patients. The trial is planned to start early 2027.

Forward Looking Statements
This release contains certain forward-looking statements relating to the business of MCC Therapeutics, Inc. that can be identified by the use of forward-looking terminology such as “believes,” “expects,” or similar expressions. Such forward-looking statements involve known and unknown risks and uncertainties, including uncertainties relating to product development, efficacy and safety, regulatory actions or delays, the ability to obtain or maintain patent or other proprietary intellectual property protection, market acceptance, physician acceptance, third party reimbursement, future capital requirements, competition in general and other factors that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. MCC Therapeutics, Inc. is under no obligation (and expressly disclaims any such obligation) to update or alter its forward-looking statements whether as a result of new information, future events or otherwise.